Patients with T2DM at risk for cardiovascular events were stratified as having normal or mildly impaired renal function ( estimated glomerular filtration rate [ eGFR ] > 50 mL/min/1 .73 m ( 2 ) ; n = 13,916 ) , moderate renal impairment ( eGFR 30-50 mL/min/1 .73 m ( 2 ) ; n = 2,240 ) , or severe renal impairment ( eGFR < 30 mL/min/1 .73 m ( 2 ) ; n = 336 ) and randomized to receive saxagliptin or placebo .